Viyash Scientific Appoints Two Carlyle Directors and Revises ESOP Pool
Viyash Scientific has strengthened its board with the appointment of two senior Carlyle group executives as Additional Non-Executive, Non-Independent Directors. The company also revised its Employee Stock Option Scheme pool, reducing it from 1,34,75,000 to 1,30,98,000 stock options under ESOP 2026.

*this image is generated using AI for illustrative purposes only.
Viyash Scientific has announced significant board changes with the appointment of two Additional Non-Executive, Non-Independent Directors representing the Carlyle group, along with revisions to its Employee Stock Option Scheme. The appointments were made based on recommendations from the Nomination and Remuneration Committee and approved during a board meeting held on April 22, 2026.
Dual Board Appointments
The company's Board of Directors approved the appointment of two senior executives from Carlyle group as Additional Directors with effect from April 22, 2026. Both appointments are subject to shareholder approval and the directors are liable to retire by rotation.
| Director Details: | Amit Jain | Abhiroop Jayanthi |
|---|---|---|
| DIN: | 06917608 | 10354445 |
| Designation: | Additional Non-Executive, Non-Independent Director | Additional Non-Executive, Non-Independent Director |
| Current Role: | Partner and Head of Carlyle India Advisors | Managing Director, Asia Private Equity team at Carlyle |
| Effective Date: | April 22, 2026 | April 22, 2026 |
Professional Backgrounds
Amit Jain's Experience
Amit Jain serves as Partner and Head of Carlyle India Advisors, overseeing Carlyle's India operations and private equity team. He leads investment and portfolio company activities across technology, consumer, advanced manufacturing and industrial sectors. Jain joined Carlyle in 2021 after a decade at Blackstone India, where he served as Senior Managing Director in the Private Equity Group.
His career began with consulting at McKinsey & Company and operating roles at Unilever in India. He currently serves on the boards of several Carlyle portfolio companies, including Quest Global, Piramal Healthcare, VLCC, Highway Roop, Varmora Granito, and Strata Geosystems, Knack Global & Adastrra. Jain was recognized by The Economic Times as one of India's "40 Under 40" young business leaders in 2019.
Abhiroop Jayanthi's Profile
Abhiroop Jayanthi is a Managing Director and member of the Asia Private Equity team at Carlyle, which manages USD 465 billion of assets under management. He advises on investments in India focusing on healthcare, life sciences, advanced manufacturing, and industrial sectors.
With 15 years of private equity experience, Jayanthi previously served as Managing Director at Bain Capital, leading investments across healthcare, life sciences, technology, and industrials sectors. He was named one of India's most promising young corporate leaders by The Economic Times in 2014. Jayanthi holds an MBA from the Wharton Business School and earned his undergraduate degree in Industrial Engineering from IIT Delhi.
ESOP Pool Revision
The Board approved a revised Employee Stock Option Scheme pool under ESOP 2026. The total number of stock options was adjusted from the originally proposed 1,34,75,000 to 1,30,98,000 stock options based on the recommendation of the Nomination and Remuneration Committee.
| ESOP Details: | Information |
|---|---|
| Original Pool: | 1,34,75,000 stock options |
| Revised Pool: | 1,30,98,000 stock options |
| Scheme Name: | Viyash Scientific Limited Employee Stock Option Scheme 2026 |
Strategic Significance
The appointment of both directors represents Carlyle group's continued involvement in Viyash Scientific's governance structure. According to the regulatory filing, both appointees have declared they are not debarred from holding director positions pursuant to any SEBI order or other authority. The Board meeting was conducted from 11:30 a.m. to 12:39 p.m. on April 22, 2026, with the company fulfilling its disclosure obligations under Regulation 30 of the SEBI Listing Regulations.
Historical Stock Returns for Viyash Scientific
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.30% | -0.65% | +15.00% | +1.60% | +39.11% | -22.12% |
What strategic initiatives might Carlyle pursue through Viyash Scientific given their focus on healthcare, technology, and advanced manufacturing sectors?
How could the reduced ESOP pool from 1.35 crore to 1.31 crore options impact employee retention and future talent acquisition strategies?
Will Carlyle's increased board representation signal potential changes in Viyash Scientific's expansion plans or acquisition strategy?


































